Navigation Links
Lupin Expands Branded Play
Date:6/30/2009

Announces Acquisition of Worldwide Rights for its first NDA - AllerNaze(TM)

BSE: 500257 NSE: Lupin REUTERS: LUPN.BO BLOOMBERG: LPC IN

MUMBAI, India, June 30 /PRNewswire/ -- Pharmaceutical Major, Lupin Ltd. announced today the acquisition of worldwide rights for the intra-nasal steroid (INS) product, AllerNaze(TM) (triamcinolone acetonide, USP) Nasal Spray, 50mcg from Collegium Pharmaceutical, Inc.

The United States will be the first market in which Lupin will launch the product. Lupin expects to expand its US sales force as it launches AllerNaze(TM), building on its presence in pediatrics and expanding into other key specialties such as allergy/immunology and otolaryngology.

The U.S. Food and Drug Administration (FDA) has already approved AllerNaze(TM) (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve (12) years of age and older. The safety and efficacy of AllerNaze(TM) in both SAR and PAR have been well established in 14 controlled clinical trials involving almost 1,200 subjects. The studies assessed the safety and effectiveness of AllerNaze(TM) in treating the symptoms (runny nose, nasal itching, sneezing, and nasal congestion) in patients with allergic rhinitis.

The United States alone reports up to 40 million cases every year that severely affect quality of life of such patients. The INS market generated $ 2.5 Billion in annual sales in United States alone (IMS data).

Commenting on the development, Dr. Kamal Sharma, Managing Director, said: "Our investment in AllerNaze(TM) reflects our commitment to expand our brand business in the US and also in some select markets. Having built a significant base in the US by leveraging our internal res
'/>"/>

SOURCE Lupin Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Lupin Receives USFDA Approval for Topiramate Tablets
2. Lupin Launches Ramipril Capsules
3. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
4. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
5. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
6. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
7. Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
8. Lupin is Granted USFDA Approval for Levetiracetam Tablets
9. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
10. Rohm and Haas Expands in India
11. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives ... Los Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate ... The facility serves meals and provides a social outlet for ... , Platinum Vice President, Mike Muench, says that the idea ... , “Platinum got its start selling long-term care insurance ...
(Date:5/21/2013)... May 21, 2013 Dimensional Insight, a ... announced that Western Maryland Health System, a ... The Diver Solution™ (Diver) to help it analyze its ... first customer to purchase Diver through Dimensional Insight’s recently ... Like most hospitals, Western Maryland has massive amounts of ...
(Date:5/21/2013)... Tools4ever, the market leader in Identity & Access ... Password Management (SSRPM) suitable for BYOD. With the latest ... on mobile systems i.e.; laptops, tablets, handheld computers and ... Windows passwords anywhere, anytime. Once the end user has ... then reset his or her own password. , ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... ─ Clinical measurement of physical activity appears to ... patients with chronic obstructive pulmonary disease (COPD) will ... study conducted by researchers in Connecticut. The study ... levels of inactivity with an increased incidence of ... of the study will be presented at the ...
Breaking Medicine News(10 mins):Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Exercise levels may predict hospitalizations in COPD population 2
... Dec. 13, Speaker Nancy Pelosi,issued the following statement ... Leader George Mitchell, which found widespread use,of steroids and ... Mitchell Report tells a troubling story of how many ... the fans of our national,pastime by using steroids and ...
... Poll Shows Rural Seniors Want E-Prescribing in Medicare, ... so many issues, promoting electronic prescribing (e-prescribing) in,Medicare ... and Democrats can,agree on. "The Medicare Electronic Medication ... require that Medicare physicians begin to,prescribe electronically, will ...
... The University of Illinois at Chicago College of Nursing has ... people as they transition to the end of life. ... the science of care for people of all ages facing ... funded through a $2.4 million grant from the National Institute ...
... side effects, including heart trouble , , THURSDAY, Dec. 13 ... Andy Pettitte, Houston Astros All-Star shortstop Miguel Tejada and ... players cited in a highly anticipated report into the ... , The report climaxed a 20-month probe by former ...
... 13 The Quantum Group,Inc. (Amex: QGP, QGP.U) ... its registered public offering, raising $13.2 million in,gross ... initiated trading,on the American Stock Exchange (AMEX) of ... "QGP.U." In addition, Quantum common shares,formerly traded on ...
... Dec. 13 Repligen Corporation,(Nasdaq: RGEN ) ... has been,elected to its Board of Directors. Dr. ... and regulatory expertise in the,development of therapeutics for ... very pleased to welcome an executive with Earl,s ...
Cached Medicine News:Health News:One Thing Washington Can Agree On: Time for E-Prescribing in Medicare 2Health News:One Thing Washington Can Agree On: Time for E-Prescribing in Medicare 3Health News:New UIC center to study end-of-life transition 2Health News:New UIC center to study end-of-life transition 3Health News:Report Finds 'Widespread Steroid Use in Baseball' 2Health News:Report Finds 'Widespread Steroid Use in Baseball' 3Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 3Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 2Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 3
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... LEESBURG, Va. , May 21, 2013 /PRNewswire/ ... than 22,000 pharmacies nationwide, announces today the publication ... Healing America,s Post-Reform Health Care System. The white ... health, reducing costs, and seeks public engagement to ... Personalized Pharmacist Care refers to a range ...
(Date:5/20/2013)... 2013 Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... of Directors declared, at its meeting on May 16, ... share for the third quarter of fiscal 2013.  The ... shareholders of record on June 7, 2013. ...
Breaking Medicine Technology:Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3Landauer, Inc. Declares Regular Cash Dividend 2
... M.D., to Moderate Discussion, Following Presentations by Tony Yaksh, Ph.D.; Jerome ... ... JOLLA, Calif., June 25 A Webinar hosted by,TorreyPines Therapeutics, Inc. ... bring together industry experts to discuss the opportunity of treating,chronic pain, ...
... Vical Incorporated,(Nasdaq: VICL ) today announced that ... three-year, $6.0 million grant awarded in,2007, and is ... manufacturing,process with the potential to produce several million ... The RapidResponse(TM) system is designed to allow extremely ...
Cached Medicine Technology:TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate 2TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate 3TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate 4Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 2Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 3Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 4Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 5
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
Medicine Products: